Cardiovascular Diseases
At Hospital Alvaro Cunqueiro, investigators are evaluating whether early use of candesartan can prevent a meaningful decline in heart function for genetic carriers of dilated cardiomyopathy, aiming to preserve left ventricular performance before symptoms appear.
- Early pharmacologic intervention in at‑risk patients
- Monitoring left ventricular ejection fraction as a primary endpoint
- Assessing ventricular remodeling through imaging biomarkers
The cardiology unit is conducting three trials with a team of 48 investigators, focusing on innovative prevention strategies for heart muscle disease.
Congenital, Hereditary, and Neonatal Diseases
The department is dedicated to studying hereditary forms of dilated cardiomyopathy, specifically targeting individuals who carry disease‑causing variants but have not yet manifested clinical signs, to evaluate the protective effect of early therapy.
- Genetic screening and identification of at‑risk family members
- Placebo‑controlled assessment of disease progression
- Long‑term safety monitoring of ARB treatment in asymptomatic carriers
With 48 researchers involved, the site’s three clinical trials aim to translate genetic insights into preventive care for inherited heart conditions.
